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Abstract
Background: Hepatitis C virus (HCV) is a leading cause of chronic liver disease, end-stage cirrhosis, and
liver cancer, but little is known about the burden of disease caused by the virus. We summarised burden
of disease data presently available for Europe, compared the data to current expert estimates, and
identified areas in which better data are needed.
Methods: Literature and international health databases were systematically searched for HCV-specific
burden of disease data, including incidence, prevalence, mortality, disability-adjusted life-years (DALYs),
and liver transplantation. Data were collected for the WHO European region with emphasis on 22
countries. If HCV-specific data were unavailable, these were calculated via HCV-attributable fractions.
Results: HCV-specific burden of disease data for Europe are scarce. Incidence data provided by national
surveillance are not fully comparable and need to be standardised. HCV prevalence data are often
inconclusive. According to available data, an estimated 7.3–8.8 million people (1.1–1.3%) are infected in
our 22 focus countries. HCV-specific mortality, DALY, and transplantation data are unavailable.
Estimations via HCV-attributable fractions indicate that HCV caused more than 86000 deaths and 1.2
million DALYs in the WHO European region in 2002. Most of the DALYs (95%) were accumulated by
patients in preventable disease stages. About one-quarter of the liver transplants performed in 25
European countries in 2004 were attributable to HCV.
Conclusion: Our results indicate that hepatitis C is a major health problem and highlight the importance
of timely antiviral treatment. However, data on the burden of disease of hepatitis C in Europe are scarce,
outdated or inconclusive, which indicates that hepatitis C is still a neglected disease in many countries.
What is needed are public awareness, co-ordinated action plans, and better data. European physicians
should be aware that many infections are still undetected, provide timely testing and antiviral treatment,
and avoid iatrogenic transmission.
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Since the discovery of the hepatitis C virus (HCV) in 1989
and its identification as one of the leading causes of
chronic liver disease with life-threatening sequelae such as
end-stage cirrhosis and liver cancer [1], questions have
been raised about the burden of disease caused by the
virus.
According to the World Health Organization (WHO),
about 3% of the world's population is infected with HCV,
with prevalence ranging from 0.1–5% in different Euro-
pean countries [2,3]. Approximately 15–25% of HCV
infections are estimated to progress to severe liver disease,
which may take more than 30 years to develop [1,4].
Acute infections and less-advanced stages of chronic dis-
ease usually are clinically silent [1,5], and only about half
of the viremic patients exhibit elevated ALT activity [6].
Therefore, hepatitis C is often first diagnosed in a late
stage when therapeutic options are already limited. Due
to the slow and silent onset many patients are unaware of
their infection. Even in France, which among European
countries most actively screens for HCV-infection, at least
40% of the infections are still undetected [7].
Liver transplantation is the only therapeutic option for
patients with end-stage liver disease [1,8]. If detected in
time, however, progression to severe liver disease can be
prevented in 54–63% (95% confidence limits ranging
from 49–68%) of patients through antiviral treatment
with peginterferon and ribavirin [9-13].
In many countries, transmission rates decreased substan-
tially with the introduction of routine blood screening in
1991 [2,14,15]. However, due to slow disease progres-
sion, many patients infected prior to the 1990s via con-
taminated blood products are still at risk to progress to
severe liver disease in future years. Therefore, despite the
decline of new infections acquired via blood products,
mathematical models still predict a continuing rise in
HCV-related morbidity and mortality [16-21]. Today,
after the eradication of transfusion-related infections,
intravenous drug use is considered as the main cause of
HCV transmission in most of European countries, with
prevalence rates among intravenous drug users (IDUs)
ranging from 15% to 90% [22-24]. In Eastern Europe,
nosocomial infections seem to play an important role as
well [22].
Burden of disease estimates are frequently cited in the lit-
erature. However, most estimates reflect provisional
expert consensus opinion, and the empirical evidence
underlying these estimates is seldom revealed. Experts
have estimated that HCV accounts for 20% of cases of
acute hepatitis, 70% of cases of chronic hepatitis, 40% of
cases of end-stage cirrhosis, 60% of cases of hepatocellular
carcinoma (HCC), and 30% of cases of liver transplants
(LT) [3] in industrialised countries. According to the
WHO, even two-thirds of liver transplants are due to HCV
infection [25] and a US consensus conference named
HCV as the primary reason for liver transplantation [26].
Motivated by the lack of reliable data needed to prioritise
public health measures, an international working group
was established to assist the WHO in estimating the global
burden of disease associated with HCV infection [27].
However, important results from this working group are
still preliminary or pending.
The objectives of this review were to: i) summarise burden
of disease data presently available for countries of the
WHO European region, including calculation of burden
of disease estimates via attributable fractions where HCV-
specific data are missing; ii) compare the data to current
expert estimates; and iii) identify areas in which better
data are needed. The burden of disease indicators we
examined were incidence, prevalence, mortality, health-
related quality of life, and liver transplantation.
Methods
Geographic Focus
Our review focused on the following 22 countries of the
WHO European region [28]: Austria, Belgium, the Czech
Republic, Denmark, Finland, France, Germany, Greece,
Hungary, Ireland, Italy, the Netherlands, Norway, Poland,
Portugal, Romania, Russia, Spain, Sweden, Switzerland,
Turkey, and the United Kingdom. When the reviewed data
sources yielded data for other countries of the region,
these were reported as well.
Literature and Data Search
Our primary goal was to retrieve data that are nationally
representative and comparable across countries.
We performed a systematic literature search up to October
2006 in Medline, PreMedline, and Embase, combining
search terms for HCV-related disease ("HCV" or "hepatitis
C" or "cirrhosis" or "hepatocellular carcinoma" or "liver
cancer"), with search terms for our predefined burden of
disease indicators (incidence, prevalence, mortality, qual-
ity of life, liver transplantation) and geographic region
(Europe, or one of our 22 focus countries). Because HCV
was first discovered in 1989, we restricted our search to
documents published since then. Documents in lan-
guages other than English or German, and studies on ani-
mals were excluded.
In addition, we reviewed reference lists of retrieved publi-
cations, searched websites of national and international
organisations (e.g., Centers for Disease Control (CDC),Page 2 of 14
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pean Association for the Study of the Liver (EASL), Euro-
pean Centre for Disease Prevention and Control (ECDC),
European Liver Transplant Registry (ELTR), European
Commission, Statistical Office of the European Commu-
nities (Eurostat), Eurosurveillance, National Institutes of
Health (NIH), Organisation for Economic Co-operation
and Development (OECD), World Health Organization
(WHO) and consulted with experts from health organisa-
tions and pharmaceutical companies to obtain data from
national sources. Consultation with experts was particu-
larly helpful in the case of prevalence.
Calculations and Reporting
In cases where aggregated burden of disease data were
reported for multi-causal disease outcomes – such as liver
cirrhosis or liver cancer – but HCV-specific data were miss-
ing, we used attributable fractions to estimate the number
and proportion of cases related to HCV infection. Cases
attributable to HCV were derived by weighting the total
number of cases with respective HCV-attributable frac-
tions. HCV-attributable fractions were derived from a
recent publication by Perz et al. [29], who estimated the
fractions of cirrhosis and hepatocellular carcinoma
(HCC) attributable to hepatitis B virus and HCV infec-
tions in the WHO sub-regions. We preferred attributable
fractions as derived by Perz et al. to those recently derived
by other researchers [30] because those by Perz et al. do
not rely on currently uncertain estimates of HCV preva-
lence. The use of regional, rather than country-specific,
attributable fractions is a simplification that may not have
a strong influence on regional burden of disease esti-
mates, but can yield inaccurate results for individual
countries.
To describe quality of life-related burden of disease, we
used disability-adjusted life-years (DALYs) and years lost
due to disability (YLDs) [31-36]. The DALY was intro-
duced by the WHO Global Burden of Disease Study
(GBD) to compare death and disability from various dis-
orders across countries. It is a measure of population
health that sums together years of life lost from premature
death in the population (YLLs) and those lost due to
being in a state of poor health or disability (YLDs) by inci-
dent cases. One DALY can be thought of as one year of
'healthy' life lost.
Retrieved and calculated burden of disease data are pre-
sented in detailed tables as additional material (see addi-
tional file 1). Evidence tables are presented for country-
specific HCV incidence and prevalence, and HCV-related
deaths, DALYs, and liver transplants. Input parameters
and steps of our calculation are made transparent in the
tables. In the main document, data are presented as
choropleth maps of the WHO European region where the
map categories represent rounded data quartiles. The
maps were compiled in SAS (release 9.1 by SAS Institute
Inc., Cary, NC, USA).
Results
Incidence
Our systematic literature search revealed a scarcity of HCV
incidence data that are comparable across countries of the
WHO European region. Pan-European HCV incidence
data available from the WHO Health for All Database
[37], which presents annual case numbers of acute hepa-
titis C (ICD-10 Code B17.1) submitted by countries of the
WHO European region, proved to be the most compara-
ble due to the use of a standardised case-definition.
Table 1 (see additional file 1) presents annual incidence
rates of acute hepatitis C reported to the WHO from the
European region. Data were available for the period 1997
to 2004. All countries except Monaco and Turkey pro-
vided at least one estimate, and only a few countries
reported data on an annual basis. Incidence data for most
countries varied with time. Data from some countries sug-
gest a decrease in incidence, whereas other countries
exhibit increases. In some countries incidence appears to
rise and fall without a trend.
To cope with temporal variation, we averaged annual inci-
dence figures reported during the observed time period
(see additional file 1, Table 1). Averaged annual incidence
rates for acute hepatitis C vary across countries from 0.00
to 39.21 cases per 100000 residents. However, the geo-
graphic distribution of incidence rates in the WHO Euro-
pean region shows no clear pattern (Figure 1). Applying a
population size weight yielded an average annual inci-
dence rate of 6.19 per 100000 (95% CI 4.90–7.48) for the
WHO European region (excluding Monaco and Turkey).
Prevalence
Though our systematic literature search for prevalence
data retrieved 335 references, almost all were considered
inappropriate due to lacking representativeness for the
general population. HCV prevalence data covering most
European countries were available from the WHO, which
published global HCV prevalence data submitted by
countries or selected from published studies in 1997 and
1999 [38,39].
WHO prevalence data for the WHO European region are
presented in Table 2 (see additional file 1). Estimates were
provided for 32 countries of the region, including all 22 of
our focus countries. Prevalence estimates range from
0.003% to 4.5%. The map compiled from the WHO data
(Figure 2) indicates high prevalence rates (> 1.2%) in
Southern and Eastern European countries, whereas lowPage 3 of 14
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European countries.
We performed plausibility checks to evaluate the quality
of WHO prevalence data. In a first plausibility check, we
checked for consistency with data from other sources (see
additional file 1, Table 2). Specifically, WHO figures were
compared to data from a review of blood donor studies in
seven European countries [40], and data from national
sources. National data were retrieved from national health
authorities or, if those were unavailable, from national
key opinion leaders. National estimates could be retrieved
for 21 of our 22 study countries, except Finland. Com-
pared to these, WHO prevalence estimates are lower for
12 countries, about equal for six, and higher for three.
Estimates from blood donor studies are substantially
higher for five countries and lower for two.
In a second plausibility check, we investigated the consist-
ency between WHO prevalence and incidence data that
were available for 30 countries (see additional file 1,
Tables 1 and 2). In order to screen for data inconsisten-
cies, we divided prevalence by incidence, which, under
steady-state assumptions, yields an estimate of disease
duration (Duration ~Prevalence/Incidence) [41,42]. Cal-
culated disease duration ranged from 0 to 23077 years.
Even though the steady-state assumption does not hold,
the extreme range indicates inconsistencies between
WHO prevalence and incidence data. Inconsistencies are
most likely in case of short disease duration, which indi-
cates that high incidence is coupled with low prevalence.
Prolonged disease duration does not necessarily reflect
data inconsistencies but might come about in countries
that have greatly reduced incidence through effective pre-
vention programs.
According to WHO prevalence data, approximately 7.3
million (1.1%) people in our 22 focus countries are esti-
mated to be infected with HCV. Based on the higher
national estimates, 8.8 million (1.3%) people are esti-
mated to be infected.
Mortality
Our systematic literature search yielded little data on
HCV-related mortality in the general population, since
studies focused primarily on mortality in risk groups and
Average annual incidence of HCV infection in countries of the WHO European region between 1997 and 2004Figure 1
Average annual incidence of HCV infection in countries of the WHO European region between 1997 and 2004. 
Source: Calculated from WHO Health for All data [37]Page 4 of 14
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try- and disease-specific mortality data were available
from the 2002 WHO GBD [43], which were derived from
vital registration statistics or other reliable sources [35].
Data for the countries of the WHO European region
include the estimated number of deaths in 2002 attribut-
able to hepatitis C infections without cirrhosis and liver
cancer [44]. As only all-cause mortality data were reported
for liver cancer and cirrhosis [44], deaths attributable to
HCV for these conditions were calculated via attributable
fractions. The total number of deaths attributed to HCV
was calculated as the sum of deaths due to hepatitis C,
HCV-related cirrhosis and HCV-related liver cancer.
Retrieved and calculated mortality data are presented in
Table 3 (see additional file 1). According to our calcula-
tions, HCV caused more than 86000 deaths in the WHO
European region in 2002, accounting for 35% of cirrhosis
and 32% of liver cancer deaths in that year. Country-spe-
cific HCV-related mortality ranges from 0.1 to 31.5 deaths
per 100000 residents. Figure 3 shows the distribution of
HCV-related death rates in the WHO European region.
High death rates (> 12 deaths per 100000) are predomi-
nantly found in the centre of the region. HCV-related liver
cancer mortality (Figure 4) displays a notable East-West
gradient, with high death rates (> 3 per 100000) in West-
ern Europe and low death rates (<= 1 per 100000) in East-
ern Europe. The death rates for HCV-related cirrhosis
(Figure 5) provide a complementary picture.
Quality of life
Our systematic literature search produced several studies
investigating health-related quality of life in patients with
hepatitis C. However, only the WHO GBD reported bur-
den of disease data that considered quality of life [43].
Available data comprised country-specific DALY [44] and
region-specific YLD estimates [45] for the year 2002. As in
the case of mortality, DALYs and YLDs were only reported
for hepatitis C without cirrhosis and liver cancer [44].
Therefore, DALYs and YLDs resulting from HCV-related
cirrhosis and liver cancer were again calculated via HCV-
attributable fractions.
DALYs and DALY rates retrieved and calculated for the
countries of the WHO European region are presented in
Table 4 (see additional file 1). Based on our calculations,
almost 1.2 million DALYs were lost due to HCV in the
WHO European region in 2002, which corresponds to an
Prevalence of HCV infection in countries of the WHO European regionFigur  2
Prevalence of HCV infection in countries of the WHO European region. Source: WHO 1999 [39]Page 5 of 14
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DALYs (81%) were lost due to HCV-related cirrhosis. Fig-
ure 6 shows the distribution of HCV-related DALY rates in
countries of the WHO European region. High rates (> 155
DALYs per 100000) predominate in Eastern countries.
We looked separately at YLDs, the disability component
of the DALY measure. YLD data were available for the
WHO European region as a whole but not for individual
countries. HCV-related YLDs were calculated similarly to
HCV-related DALYs by using the regional HCV-attributa-
ble fractions for cirrhosis (35%) and liver cancer (30%)
derived from our DALY calculation. According to our cal-
culations, HCV caused 200104 YLDs in the WHO Euro-
pean region in 2002. Of those YLDs, 6250 (3%) were due
to hepatitis C without cirrhosis or liver cancer, 191537
(96%) were due to HCV-related cirrhosis and 2317 (1%)
were due to HCV-related liver cancer.
Liver transplantation
Because our systematic literature search did not yield
Europe-wide HCV-specific data on liver transplants, these
were calculated using data from various sources. We
obtained the number of liver transplants performed in
2004 in 25 countries of the WHO European region,
including 21 of our focus countries, from the Transplant
Committee of the Council of Europe (TCCE) [46]; data
were not available for the Russian Federation. Data on the
distribution of indications for transplantation – including
all-cause acute hepatic failure, cirrhosis, and liver cancer –
were retrieved from the European Liver Transplant Regis-
try (ELTR) [47]. HCV-attributable fractions were applied
to obtain HCV-specific indication data. To derive num-
bers of HCV-related transplants, we weighted total num-
bers of liver transplants by all-cause indication and HCV-
attributable fraction. Transplants due to virus-related
acute hepatic failure were disregarded due to minor rele-
vance and insufficient data.
Input and calculated data are presented in Table 5 (see
additional file 1). According to the TCCE, 6411 liver trans-
plants were performed in the 25 countries in 2004. Based
on our calculations, 23% of those were attributable to
HCV. HCV-related transplantation rates varied from
0.002 to 0.563 per 100000 residents (rates not shown in
tables).
HCV-related death rates in countries of the WHO European region in 2002Figure 3
HCV-related death rates in countries of the WHO European region in 2002. Source: Calculated from WHO GBD 
data [44]Page 6 of 14
(page number not for citation purposes)
BMC Public Health 2009, 9:34 http://www.biomedcentral.com/1471-2458/9/34Data illustrating the increasing shortage of donor organs
for liver transplantation were retrieved from Eurotrans-
plant, a mediation centre for organ donations active in
seven European countries. As shown by Figure 7, the
demand for liver transplantation (reflected by the waiting
list) constantly increased over the last decade, whereas the
number of transplantations (reflecting the organ supply)
was stagnant.
Discussion
Data on the burden of disease of hepatitis C in Europe are
scarce, outdated or inconclusive. By revealing the paucity
of available information, our study indicates that hepatitis
C is still a neglected disease in many countries. The find-
ings are relevant for physicians, researchers and health
care decision makers concerned with hepatitis C virus
infection in Europe.
Since our calculations are based on uncertain input data
from various external sources and simplifying assump-
tions, our results are open to debate. A particular limita-
tion of our analysis is the use of regional rather than
country-specific HCV-attributable fractions. This may not
have a strong influence on regional burden of disease esti-
mates but can yield inaccurate results for individual coun-
tries. However, as attributable fractions are currently
unavailable for many countries of the WHO European
region, there was no alternative to using aggregated attrib-
utable fractions in order to estimate the HCV-related bur-
den of disease for our selection of 22 countries or the
WHO European region as a whole. Although, the quality
of our input data strongly limits the inter-country compa-
rability of our results, we present burden of disease esti-
mates for individual countries in our tables. Since all
parameters of our calculations have been made explicit,
country-specific estimates can easily be revised by the
interested reader as better data become available. Thus
our results and tables could serve as a starting point for
improved data collection and eventually, might contrib-
ute to move forward public health and patient care.
Incidence
Incidence data are usually assessed by surveillance sys-
tems. However, although hepatitis C is a notifiable disease
in most countries of the WHO European region, no uni-
form hepatitis C surveillance exists at the European level
Death rates for HCV-related liver cancer in countries of the WHO European region in 2002Figure 4
Death rates for HCV-related liver cancer in countries of the WHO European region in 2002. Source: Calculated 
from WHO GBD data [44]Page 7 of 14
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lance are hardly comparable across countries due to differ-
ent surveillance systems and case definitions [48-51].
Heterogeneous surveillance causes geographic variation
of incidence estimates. Temporal variation might be due
to changes in reporting behaviour, modifications of the
surveillance system or case definitions, and increased sen-
sitivity of tests (e.g., 2nd and 3rd generation anti-HCV
assays). Variation and trends in incidence are therefore
difficult to interpret [49].
A general problem for HCV surveillance is its poor sensi-
tivity [3,5,51] resulting from under-detection and -report-
ing. Under-detection primarily results from the slow and
silent onset of the disease [49,52]. Under-reporting has
been described as a consequence of political unrest, disin-
terest, and poorly developed infrastructures [53,54]. Due
to the insensitivity of hepatitis C surveillance, HCV attack-
rates are systematically underestimated [55], especially if
surveillance focuses only on acute infections which are
rarely symptomatic. Targeted screening programs could
improve the sensitivity of surveillance and reduce the
number of undetected cases. Second-generation surveil-
lance as proposed for HIV might help to understand and
prevent the spread of the HCV epidemic [56].
Presently, the most comprehensive collection of Euro-
pean incidence data applying a uniform case definition is
produced by the WHO [37]. Per definition, WHO data
represent cases of acute hepatitis C, which in theory most
closely approximate the incidence of HCV infections.
However, since not all countries reporting to WHO in the
past were able to distinguish acute from chronic cases
[57], there is serious doubt that all cases truly meet the
case definition. As newly diagnosed or reported cases of
chronic hepatitis might have been misclassified as acute
cases, WHO data do not necessarily reflect true incidence
rates. Substantial variation of the reported incidence esti-
mates suggest that the data are highly unreliable, which
strongly impairs inter-country comparability as well.
Based on WHO data, the population-weighted average
annual incidence for acute hepatitis C in the WHO Euro-
pean region is 6.19 per 100000 residents (95% CI 4.90–
7.48). Expert estimates and alternative data available for
selected European countries are not always consistent
with WHO incidence data [3,48,58]. However, consider-
Death rates for HCV-related liver cirrhosis in countries of the WHO European region in 2002Figure 5
Death rates for HCV-related liver cirrhosis in countries of the WHO European region in 2002. Source: Calcu-
lated from WHO GBD data [44]Page 8 of 14
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ficult to decide which data are most valid.
In general, incidence data focussing on acute infections do
not appropriately reflect the size of the hepatitis C prob-
lem because many infections were acquired through con-
taminated blood products prior to the 1990s. Therefore,
even in countries with presently low transmission rates,
the prevalence of hepatitis C might be high.
Prevalence
Given that many infections were contracted in the past,
HCV prevalence is the key measure in quantifying the size
of the hepatitis C problem and guiding health care
resource planning. In contrast to incidence data which are
collected by surveillance systems, the assessment of prev-
alence requires representative population surveys. Even
studies assessing the prevalence in blood donors are prob-
lematic, since high-risk groups such as intravenous drug
users are often excluded from blood donation, leading to
an underestimation of the true prevalence in the popula-
tion [59]. HCV prevalence assessed in population surveys
can easily be underestimated as well, if there is selection
bias regarding high risk groups like IDUs [60,61]. There-
fore, some countries have corrected prevalence estimates
for selection bias.
Our investigation suggests that, the WHO should cur-
rently be considered as the most comprehensive source of
European HCV prevalence data because their data were
collected by a sole authority with uniform demands on
data quality, and comparable data collections are lacking.
Nevertheless, it is widely accepted that current data do not
necessarily represent true HCV prevalence and are in need
of updating [27,29,39,59]. Additionally, the lack of age-
specific prevalence data needed for burden-of-disease pro-
jections has been criticised.
As revealed by our investigation, 1999 WHO prevalence
data frequently differ from estimates from other sources
and are not always consistent with incidence data, under-
scoring the uncertain data quality. While identifying
which specific prevalence data are incorrect was beyond
the scope of our study, our investigation indicates that
WHO data for Europe tend to be lower than prevalence
data from other sources. That is, estimates communicated
HCV-related DALY rates in countries of the WHO European region in 2002Figure 6
HCV-related DALY rates in countries of the WHO European region in 2002. Source: Calculated from WHO GBD 
data [44]Page 9 of 14
(page number not for citation purposes)
BMC Public Health 2009, 9:34 http://www.biomedcentral.com/1471-2458/9/34by experts in the field [62,63], results from prevalence
studies published after 1999 [6,64-68], and most interest-
ingly, data communicated on national levels, are all often
higher than WHO estimates. This finding is important
because WHO data are disseminated on an international
level and used widely in research and health policy, as
demonstrated by several recent publications referring to
the 1999 WHO data [14,30,51,59]. The reasons for which
WHO prevalence data for most countries deviate from
national estimates are unclear. While it is possible that
national information is not effectively passed on to the
international level, concerns about data validity and/or
comparability must be considered as well. Evaluating the
quality of national prevalence estimates is difficult
because those estimates are often reported only in context
documents without clear description of the underlying
data source(s). An explanation for this may be that
national prevalence estimates are based on a variety of
study results and modelling assumptions, when repre-
sentative population surveys are lacking or correction for
selection bias is needed.
Applying WHO and national prevalence data, we esti-
mated that 1.1% to 1.3% of the population in our 22
focus countries are infected with HCV. However, as our
selection of countries is arbitrary, this prevalence may not
be applicable for the WHO European region as a whole.
Further studies assessing the age-specific HCV prevalence
in representative population samples are needed, and
data disseminated on the international level should be
updated.
Mortality
According to our investigation, HCV-specific mortality in
Europe has not yet been sufficiently assessed. According to
our calculations, HCV caused more than 86000 deaths in
the WHO European region in 2002. This is about the
same number of deaths attributed to pancreas cancer
(ICD-10 Code C25) and more than twice the number esti-
mated for HIV/AIDS (ICD-10 Code B20-B24) [69].
HCV was estimated to account for 35% of cirrhosis and
32% of liver cancer deaths, respectively. The latter is not
consistent with the frequently cited statement that HCV
accounts for 60% of hepatocellular carcinomas [3,25].
Since HCC is the most frequent type of liver cancer [70]
and survival with liver cancer is short [71], the proportion
of liver cancer deaths due to HCV should approximate the
HCV-attributable fraction for liver cancers, which in our
analysis ranged from 15 to 44%. As these fractions repre-
sent regional averages, our estimate of HCV-related liver
cancer deaths might be inaccurate for individual coun-
Liver transplants and waiting list 1991 to 2004Figure 7
Liver transplants and waiting list 1991 to 2004. Source: EurotransplantPage 10 of 14
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attributable fractions between 50% and 70% [72-74].
Our data show opposite East-West gradients for HCV-
related cirrhosis and liver cancer mortality, with lower
HCV-related cancer mortality in the East. This might be
the result of a competing risk situation in which patients
in the East die from cirrhosis before developing liver can-
cer. HCV-related cirrhosis mortality might be higher due
to concomitant excess alcohol consumption [75]. An
alternative explanation would be that HCC in Eastern
Europe is under-detected or misclassified as cirrhosis,
which is likely because state-of-the-art imaging technol-
ogy is less frequently available.
In general, geographic variation of HCV-related mortality
rates may be caused by differences in HCV prevalence.
However, heterogeneous data quality, deviating health
care standards, or differences in the distribution of com-
peting and synergistic risk factors should be considered as
alternative explanations. For example, HCV-related death
rates might be lower in countries with high prevalence of
hepatitis B [2] and higher in countries with a high level of
alcohol consumption [75]. Specifically, heavy alcohol
consumption has been shown to be associated with
higher risks of cirrhosis, liver cancer and death in patients
with chronic hepatitis C [29,76].
Generally, our mortality data represent crude estimates
that are unadjusted for potential co-factors. Therefore, dis-
cussion of HCV-related deaths does not exclude the
involvement of other risk factors or co-disease.
Quality of life
Presently, the only data allowing a consistent cross-coun-
try comparison of burden of disease resulting from HCV-
related quality of life impairment are DALYs and YLDs
estimated by the WHO GBD in 2002. No expert estimates
are available for such a burden. HCV-related DALYs and
YLDs reported by the GBD are low due the exclusion of
cases with cirrhosis and liver cancer. When these cases are
included – as in our analysis – the picture changes dramat-
ically. According to our calculations, HCV caused approx-
imately 1.2 million DALYs in the WHO European region
in 2002, of which about one sixth (200104 YLDs) are
attributed to quality of life impairment. Comparing this
figure to DALYs reported by the WHO GBD for other dis-
eases reveals that hepatitis C is a major health problem,
which is almost as big as HIV/AIDS (ICD-10 Code B20-
B24) or stomach cancer (ICD-10 Code C16), each causing
about 1.4 million DALYS in 2002 [77].
High DALY rates are predominantly found in Eastern
European countries where HCV-related cirrhosis mortality
is high but HCV-related liver cancer mortality is low. This
finding can be partially explained by the nature of the
DALY measure itself which puts strong weight on life-
years lost due to premature death. Thus, our results imply
that hepatitis C patients in Eastern European countries die
at a younger age, on average, than their Western European
counterparts.
Roughly 95% of the HCV-related DALYs were accumu-
lated by patients in advanced disease stages (cirrhosis or
liver cancer). This figure highlights the importance and
potential benefit of antiviral treatment, which can prevent
disease progression and advanced liver disease. This result
seems surprising, as several studies have shown that HCV
infection diminishes health-related quality of life even in
the absence of advanced liver disease [78-84] and there
are more patients with mild than with severe disease. Our
data suggest that quality-of-life impairment caused by
HCV infection is less relevant from a burden of disease
perspective, because (1) the DALY measure gives a strong
weight on life-years lost due to premature death, (2) disa-
bility weights applied by the Global Burden of Disease
study for advanced stages – consistently with published
patient-derived quality-of-life indices (utilities) [85,86] –
were 3 to 11 times higher then those applied for early
stages, and most importantly, (3) YLDs, the disability
component of the DALY measure, focus only on incident
cases. However, uncertainty remains, as it is unclear which
conditions and aspects are covered by the disability
weight of 0.075 [35] that was used for the calculation of
hepatitis C-related DALYs in the GBD and the estimation
of YLDs (and, by extension, DALYs) required a broad set
of input data from a multitude of sources [87].
Liver transplantation
Due to the lack of comprehensive data, HCV-related liver
transplantations in Europe were calculated using input
data from various sources. According to our calculations,
about one-quarter of liver transplants in Europe are
related to HCV.
Although this figure is lower than previous expert esti-
mates [3,88], under-estimation from our data seems
unlikely considering that our calculations are based on
the assumption that 34% to 38% of cirrhosis-related
transplants are due to HCV, while ELTR reported a much
lower fraction of 16% [47]. However, results of our calcu-
lations are limited by the use of uncertain input data and
simplifying assumptions. Additionally, our estimates
might not be valid for individual countries due to the use
of regionally aggregated HCV-attributable fractions.
Even with an attributable fraction of 23%, HCV is a dom-
inant reason for liver transplantation. Considering the
already-existing shortage of donor organs [47,89] and that
many HCV infections acquired prior to the 1990s havePage 11 of 14
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for health care action, such as timely antiviral treatment of
hepatitis C patients, is obvious. As suggested by models
projecting the incidence of HCV-related cirrhosis and liver
cancer, the need for liver transplantation will continue to
rise considerably over the next 10 to 20 years without
treatment [16-19].
According to our data, HCV-related transplantation rates
in the European region vary considerably independent of
HCV prevalence. This might indicate asymmetric report-
ing quality or unequal access to liver transplantation.
As shown by our review, European data on HCV-related
liver transplants, like HCV-related burden of disease data
in general, are poor. However, while the improvement of
incidence, prevalence, mortality and DALY data requires
considerable efforts, reliable HCV-related transplant data
could easily be generated by collecting little additional
HCV-specific information. This task could either be
adopted by the Transplant Committee of the Council of
Europe (TCCE) or the European Liver Transplant Registry
(ELTR).
Conclusion
Our results indicate that hepatitis C is a major health
problem and highlight the importance of timely antiviral
treatment. However, data on the burden of disease of hep-
atitis C in Europe are scarce, outdated or inconclusive. By
revealing the paucity of available information, our study
indicates that hepatitis C is still a neglected disease in
many countries. What is needed are public awareness, co-
ordinated action plans, and better data. As the implemen-
tation of national action plans will take time, awareness
among physicians is crucial. Specifically, physicians
should be aware that many infections are still undetected,
provide timely testing and antiviral treatment, and avoid
iatrogenic transmission. Our results could serve as a foun-
dation for improved data collection in the future.
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